Exploring the mechanisms of bacterial resistance. Implications for treatment strategies and public health

Nº de DOI: 10.34896/RSI.2025.45.22.001

AUTHORS

1. Celene Lisseth Larcos Herrera. General Practitioner. Master in Education, Technology and Innovation. Attached to the Zapotillo Health Centre. Independent Researcher at the Matilde Hidalgo of Procel Research and Teaching Department. Graduate of the Central University of Ecuador. (Latacunga-Ecuador). https://orcid.org/0000-0003-3479-6206
2. Jennifer Estefanía López Naveda. Biotechnologist Engineer. Attached to Private Clinics of Ecuador. Graduated from the Technical University of Ambato. (Ambato -Ecuador). https://orcid.org/0009-0007-5583-866X
3. Sharon Maite García Acosta. Dentist. Attached to the Telimbela Health Centre. Graduate of the National University of Chimborazo. (Ambato-Ecuador). https://orcid.org/0009-0002-8490-9053
4. Jessica Paola Montero Moposita. Nurse. Master’s Degree in Nursing Unit Management. Master’s Degree in Nursing with a specialisation in Surgical Nursing. Attached to the General Teaching Hospital Ambato. Graduate of the State University of Bolivar. (Guaranda-Ecuador). https://orcid.org/0009-0006-8894-7806
5. Josselyn Araceli Chicaiza Changoluisa. Nurse. Attached to the Delicia Health Centre. Graduate of the Central University of Ecuador. (Saquisilí -Ecuador). https://orcid.org/0009-0004-5430-9625
6. Carlota Alexandra Rivera Jarrin. General Practitioner. Master in Aesthetic, Regenerative and Anti-Aging Medicine. Attached to Private Clinics of Ecuador. Graduated from the Higher Polytechnic School of Chimborazo. (Riobamba -Ecuador). https://orcid.org/0009-0001-5691-2100
7. Jennifer Geovanna Salazar Gongora. Integral Community Medical Doctor. Attached to the Delfina Torres of Concha General Hospital. Graduate of the National Experimental University of the Central Plains Romulo Gallegos. (Esmeraldas-Ecuador). https://orcid.org/0009-0000-6734-026X

ABSTRACT

This paper aims to delve into the intricate mechanisms of bacterial resistance, evaluate the implications for treatment strategies, and outline the public health challenges and solutions necessary to combat this pressing issue.

KEY WORDS

Bacterial resistance mechanisms, antibiotic resistance, multidrug-resistant bacteria, treatment strategies for resistant infections and public health impact of bacterial resistance.

RESUMEN

Este artículo busca profundizar en los complejos mecanismos de la resistencia bacteriana, evaluar sus implicaciones para las estrategias de tratamiento y describir los desafíos y soluciones de salud pública necesarios para combatir este problema acuciante.

PALABRAS CLAVE

Mecanismos de resistencia bacteriana, resistencia a los antibióticos, bacterias multirresistentes, estrategias de tratamiento para infecciones resistentes e impacto de la resistencia bacteriana en la salud pública.

INTRODUCTION

The phenomenon of bacterial resistance poses a significant threat to global health, complicating the effective treatment of infections and leading to increased morbidity and mortality. Understanding the mechanisms underlying this resistance is crucial for developing effective treatment strategies and safeguarding public health. Bacterial resistance emerges from a complex interplay of genetic factors, whereby certain genes confer the ability to withstand antibiotics, and these resistance genes can be acquired and transferred among bacterial populations through horizontal gene transfer. Moreover, the role of efflux pumps—proteinaceous structures that expel antimicrobial agents from bacterial cells—further exacerbates this challenge, allowing bacteria to survive even in the presence of therapeutic drugs. As resistance continues to evolve, it necessitates a reevaluation of current treatment paradigms; adapting existing therapies and exploring the potential of combination therapy may provide avenues to counteract these resistant strains effectively. Additionally, the ongoing battle against bacterial resistance raises critical concerns regarding the development of new antibiotics, as the pharmaceutical industry faces significant hurdles in bringing novel treatments to market. On a public health level, monitoring the spread of bacterial resistance is fraught with challenges, particularly within healthcare settings where infection control practices are paramount. The implications of resistance extend into community settings as well, where proactive strategies are essential to mitigate the transmission of resistant bacteria.

OBJECTIVE

Delve into the intricate mechanisms of bacterial resistance, assess the implications for treatment strategies, and outline the public health challenges and solutions needed to combat this pressing problem.

METHODOLOGY

This scientific review adopts a systematic approach to analyzing the mechanisms of bacterial resistance and their implications for treatment strategies and public health. A comprehensive literature search is conducted using academic databases such as PubMed, Scopus, Web of Science, and Google Scholar to identify peer-reviewed articles, clinical studies, and systematic reviews published within the last two decades. The search includes keywords such as “bacterial resistance mechanisms”, “antibiotic resistance”, “multidrug-resistant bacteria”, “treatment strategies for resistant infections” and “public health impact of bacterial resistance.” Articles are selected based on their relevance, methodological rigor, and contribution to understanding bacterial resistance.

The review is structured into three main sections: mechanisms of bacterial resistance, clinical and pharmacological strategies to counteract resistance, and the broader public health implications. The first section examines the molecular and genetic mechanisms that enable bacteria to develop resistance to antimicrobial agents. Key topics include enzymatic degradation of antibiotics (e.g., β-lactamases), target site modifications, efflux pump systems, and horizontal gene transfer. Studies on resistance in common pathogens, such as Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae, are analyzed to illustrate how these mechanisms contribute to treatment failures.

The second section evaluates current and emerging strategies to combat bacterial resistance. This includes the development of novel antibiotics, combination therapies, bacteriophage therapy, and the use of antimicrobial peptides. The efficacy of alternative treatment approaches, such as immune-based therapies and probiotic interventions, is reviewed to assess their potential role in managing resistant infections. Pharmacokinetic and pharmacodynamic considerations are also analyzed to understand how dosing strategies and drug modifications can help overcome resistance.

The third section explores the public health impact of bacterial resistance, highlighting global trends, surveillance programs, and policy interventions. The role of antimicrobial stewardship programs, infection prevention measures, and vaccination strategies in controlling the spread of resistant bacteria is critically assessed. The review also examines the socioeconomic burden of antibiotic resistance, including increased healthcare costs, prolonged hospital stays, and mortality rates.

By integrating microbiological, clinical, and public health perspectives, this review aims to provide a comprehensive analysis of bacterial resistance and its far-reaching consequences. The synthesis of findings contributes to a better understanding of how bacterial resistance develops, spreads, and can be mitigated through targeted interventions. The review also highlights areas for future research, emphasizing the need for interdisciplinary collaboration to address the growing threat of antimicrobial resistance worldwide.

RESULTS 

Mechanisms of Bacterial Resistance:

What genetic factors contribute to bacterial resistance?

The genetic factors contributing to bacterial resistance are multifaceted, involving both intrinsic and acquired mechanisms that are deeply interconnected with environmental factors. Intrinsic resistance, though less prevalent than acquired resistance, originates from environmental bacteria that inherently produce and release antibacterial substances, thereby influencing competing microbial populations¹. This resistance is often pre-existing in nature, as evidenced by the discovery of various antibiotic resistance genes such as VanA in ancient permafrost sediments, which suggests that these genes predate modern clinical antibiotic use¹. Acquired resistance, on the other hand, typically arises under selective pressure from antibiotic usage and is facilitated by genetic determinants within bacterial communities that specify resistance to various antimicrobial drugs¹. These genetic determinants spread through mechanisms such as horizontal gene transfer, where successful gene-transmission elements like plasmids and integrons persist and disseminate even in the absence of antibiotics¹. The ability of bacteria to transfer resistance genes horizontally allows for the independent transmission of these genes, further embedding resistance into different environments¹. Consequently, the spread of antibiotic resistance is not confined to clinical settings but occurs across diverse ecosystems, including agricultural and pristine environments, pointing to the need for comprehensive strategies that address antibiotic usage and environmental contamination to mitigate the proliferation of resistance genes.

How do bacteria acquire and transfer resistance genes?

The acquisition and transfer of antibiotic resistance genes (ARGs) in bacteria occur primarily through horizontal gene transfer (HGT), which is a fundamental process contributing to bacterial evolution and the dissemination of resistance genes². HGT can transpire via three main mechanisms: conjugation, transformation, and transduction. During conjugation, genetic material is transferred through direct contact between bacterial cells, often mediated by conjugative plasmids that utilize a pilus to connect with a recipient cell, facilitating the exchange of entire chromosomes or plasmids^2,3. Transformation involves the uptake of free DNA from the environment by a competent bacterium, which can then integrate this genetic material into its own genome if it is beneficial, such as an antibiotic resistance gene^3,4. Transduction, another mechanism, involves the transfer of DNA via bacteriophages, which can insert the DNA into a recipient bacterium’s chromosome as a prophage, allowing it to replicate and potentially spread resistance genes^2,3. These processes not only highlight the adaptability of bacteria in acquiring resistance but also underscore the importance of understanding and mitigating HGT to control the proliferation of antibiotic-resistant bacterial strains. The rapid spread of resistance facilitated by HGT calls for targeted interventions to curb the transmission of ARGs, emphasizing the need for stringent antibiotic stewardship and the development of alternative therapeutic strategies.

What role do efflux pumps play in bacterial resistance?

Efflux pumps play a crucial role in bacterial resistance by actively expelling a wide range of substances, including antibiotics, from the bacterial cell, thus decreasing their intracellular concentrations and diminishing their effectiveness⁵. These transport proteins contribute to multidrug resistance, a significant public health challenge, by providing bacteria with the ability to withstand various antimicrobials and biocides⁶. Among the six major families of efflux pumps, the resistance-nodulation-division (RND) family is particularly noteworthy for its role in antibiotic resistance in Gram-negative bacteria, accommodating a broad spectrum of antimicrobials and facilitating their expulsion from the cell⁵. The RND efflux pumps, such as MexB and MexY in Pseudomonas aeruginosa, are instrumental in reducing the effectiveness of antibiotics by actively transporting them out of the bacterial cell⁷. Given the substantial impact of efflux pumps on bacterial resistance, there is a critical need to develop inhibitors that target these systems. Such inhibitors could potentially lower the minimum inhibitory concentrations of antibiotics, thereby restoring their efficacy against resistant bacterial strains⁸. This highlights the importance of continued research and development in understanding the genetic and structural basis of efflux pump-mediated resistance, which could lead to novel therapeutic strategies to combat antibiotic resistance⁹.

Implications for Treatment Strategies:

How can current treatments be adapted to overcome bacterial resistance?

Current treatments can be adapted to overcome bacterial resistance by focusing on the genetic basis of resistance, which offers a promising strategy in the fight against challenging bacterial infections. By targeting specific genes responsible for resistance to existing drugs, researchers can develop treatments that are not only more effective but also proactive in anticipating bacterial adaptations¹⁰. This genetic approach is crucial as it may reduce the likelihood of contributing to further resistance, helping to maintain the efficacy of antibiotics over time¹⁰. Moreover, the integration of phage therapy with antibiotics presents an innovative avenue to combat resistance. Phage therapy, by targeting surface proteins important for antibiotic resistance, can cause a shift in bacterial populations, making them more susceptible to antibiotics¹¹. This dual approach, combining distinct selective pressures from both phage and antibiotic therapies, has shown promise in curbing the development of resistance, providing a dynamic and evolving solution to the problem¹¹. To ensure these strategies are successful, ongoing investment in genetic research and phage therapy development is essential, potentially transforming the landscape of bacterial infection treatment.

What are the potential benefits of combination therapy in managing resistant bacteria?

The potential benefits of combination therapy in managing resistant bacteria are substantial, particularly in its ability to enhance the efficacy of antibiotics against formidable bacterial adversaries. By employing two or more drugs together, combination therapy can leverage possible synergistic effects that result in greater antibacterial control than when antibiotics are used individually^12,13. This approach is particularly promising in targeting resistant Gram-negative bacteria, which are often difficult to treat with standard antibiotic regimens¹². Additionally, combination therapy can potentially restore or increase the efficacy of antibiotics, thereby offering a viable solution to combat resistant bacterial infections¹². However, the application of combination therapy must be carefully managed due to the potential for adverse drug effects and increased treatment costs, which necessitates a balanced approach between effectiveness and safety¹³. Moreover, the strategic use of combination therapy can also play a critical role in slowing the acquisition of drug resistance, making it an essential tool in the broader effort to manage antibiotic resistance¹⁴. As research continues to explore the optimal timing and combinations of antibiotics, it is clear that combination therapy holds significant promise in the fight against resistant bacteria, although further studies are needed to solidify its role in clinical practice.

How does bacterial resistance impact the development of new antibiotics?

The impact of bacterial resistance on the development of new antibiotics is profound, as it complicates the process of creating effective treatments against infections. Understanding the mechanisms of bacterial resistance is crucial, as it allows researchers to predict and prevent the development of resistance to new antibacterial treatments [15]. This understanding is essential not only for developing drugs that bacteria do not already have resistance to but also for designing antibiotics that can circumvent or inhibit these resistance mechanisms¹⁵. As bacteria have demonstrated an ability to adapt rapidly to new antibiotics, this poses a significant challenge, necessitating continuous innovation in drug development to stay ahead of evolving bacterial defenses^16,17. Complicating matters further, bacteria can share resistance mechanisms across different species, which can quickly render new antibiotics ineffective¹⁶. This intricate web of bacterial adaptation and gene sharing underscores the need for collaborative efforts between academia and industries at both national and international levels to effectively address these challenges¹⁷. An integrated approach, which includes the development of novel antibiotics and vaccines, is crucial in combating antimicrobial resistance (AMR) and ensuring the sustainability of infection control measures¹⁷.

Public Health Implications:

What are the challenges in monitoring bacterial resistance on a public health level?

One of the core challenges in monitoring bacterial resistance on a public health level is the fragmented nature of data collection, which hinders the ability to provide accurate and representative information for policymakers to make informed decisions¹⁸. This fragmentation is exacerbated by the absence of robust health information systems, which are crucial for effective tracking and analysis of resistance trends¹⁸. As a result, low- and middle-income countries, in particular, encounter significant difficulties due to weak laboratory capacity and limited resources, which restrict their ability to conduct comprehensive surveillance and respond to the growing threat of antimicrobial resistance¹⁸. These limitations are compounded by poor governance within health systems, further complicating efforts to monitor and manage resistance effectively¹⁸. The lack of comprehensive, population-based surveillance data on antimicrobial resistance is a critical gap, as it prevents the early detection of outbreaks and the establishment of effective national health policies¹⁸. Addressing these challenges requires tailored and incremental approaches to strengthen population-based surveillance efforts in each country, ensuring that data collection systems are improved, resources are allocated effectively, and governance structures are enhanced to support a more coordinated and comprehensive response to bacterial resistance¹⁸.

How does bacterial resistance affect infection control practices in healthcare settings?

The emergence of bacterial resistance significantly affects infection control practices in healthcare settings, primarily through the interaction between microorganisms, patients, and the hospital environment¹⁹. One of the core challenges is the cross colonization of patients via the hands of healthcare staff, which facilitates the spread of resistant bacteria and undermines infection control efforts¹⁹. This problem is exacerbated by the improper use of antibiotics within these settings, which contributes to the development and proliferation of antibiotic-resistant strains¹⁹. Consequently, infection control practices must adapt to address these challenges by integrating improved surveillance and timely detection of resistant strains, which are crucial for effective management and control measures¹⁹. Additionally, there is a pressing need for aggressive control of the transmission of epidemic-resistant bacteria to maintain effective infection control, which necessitates comprehensive strategies and interventions¹⁹. Implementing these measures requires multidisciplinary cooperation to develop and enforce local policies on antibiotic use and infection control, bridging gaps in current practices and ensuring a cohesive approach to combating bacterial resistance¹⁹.

What strategies can be implemented to reduce the spread of resistant bacteria in communities?

To curtail the spread of resistant bacteria, a multifaceted approach prioritizing prevention and rapid response is essential. Vaccination emerges as a highly effective strategy, significantly reducing the incidence of infections caused by resistant bacteria by preventing disease onset²⁰. Complementary to vaccination efforts, implementing rigorous hand hygiene practices in community settings plays a crucial role in controlling the dissemination of resistant germs, which can be easily transmitted through direct contact²⁰. Additionally, public health prevention programs specifically targeting resistant bacteria can substantially slow their spread and save lives, highlighting the importance of community-level interventions²⁰. However, these strategies must be supported by educational campaigns aimed at both healthcare professionals and the general public to promote the rational use of antibiotics and prevent their overuse and misuse²⁰. This comprehensive approach not only addresses the immediate need to reduce resistant bacterial infections but also establishes a sustainable framework for maintaining the efficacy of current treatment options. Through coordinated efforts, including national and international collaboration, the global community can effectively combat antibiotic resistance and safeguard public health¹⁷.

DISCUSSION

The intricate mechanisms underlying bacterial resistance present significant challenges to both treatment strategies and public health initiatives. The dual nature of resistance—intrinsic and acquired—highlights the need for a nuanced understanding of bacterial behavior in various environments. While intrinsic resistance remains relatively rare, its roots in the natural antibacterial production of certain bacteria underscore the evolutionary adaptations that allow for survival in hostile settings. Conversely, acquired resistance, which emerges under the selective pressure of antibiotic use, illustrates a pressing public health concern, particularly as it is largely propagated through horizontal gene transfer mechanisms. This transfer not only complicates the treatment of infections but also necessitates innovative approaches to antibiotic development, which must account for the rapid evolution of bacterial genomes. The role of efflux pumps in mediating multidrug resistance, particularly in Gram-negative bacteria, calls for the urgent development of inhibitors that can enhance the efficacy of existing antibiotics. Moreover, the implementation of combination therapy emerges as a promising strategy, yet it must be approached with caution to mitigate adverse effects and manage healthcare costs effectively. The challenges of monitoring bacterial resistance, particularly in low- and middle-income countries, highlight critical gaps in data collection and resource allocation that hinder the establishment of effective national health policies. Such fragmentation not only impedes timely responses to outbreaks but also compromises the overall effectiveness of infection control practices within healthcare settings, where cross-colonization poses a significant risk. Therefore, a multifaceted public health strategy that includes vaccination, rigorous hygiene practices, and educational campaigns promoting the rational use of antibiotics is essential to curb the overuse and misuse of these critical medications. Future research must focus on bridging these gaps by fostering international collaboration and enhancing surveillance capabilities, thereby ensuring a comprehensive and coordinated response to the growing threat of antibiotic resistance. In sum, addressing bacterial resistance necessitates an integrated approach that encompasses an in-depth understanding of resistance mechanisms, the adaptation of treatment protocols, and robust public health strategies, all of which are essential for safeguarding global health in the face of this escalating crisis.

CONCLUSIONS

1. Bacterial resistance remains a critical global health challenge, significantly impacting the effectiveness of antimicrobial treatments and posing serious threats to public health. This review highlights the complex mechanisms by which bacteria develop resistance, including enzymatic degradation of antibiotics, target site modifications, efflux pumps, and horizontal gene transfer. The adaptability of bacteria to antimicrobial agents underscores the urgent need for innovative strategies to combat resistance and preserve the efficacy of existing treatments.
2. Current therapeutic approaches, including novel antibiotics, combination therapies, and alternative treatments such as bacteriophage therapy and antimicrobial peptides, show promise in addressing resistant infections. However, the rapid evolution of resistance mechanisms necessitates continuous research and development to stay ahead of emerging threats. Pharmacokinetic and pharmacodynamic considerations also play a crucial role in optimizing treatment regimens to reduce the risk of resistance while ensuring patient safety and efficacy.
3. Beyond clinical management, the public health implications of bacterial resistance are profound. The rising prevalence of multidrug-resistant pathogens increases healthcare costs, prolongs hospital stays, and elevates mortality rates worldwide. Effective antimicrobial stewardship programs, infection prevention measures, and global surveillance efforts are essential in mitigating the spread of resistance. Public awareness and education on the responsible use of antibiotics in both human and veterinary medicine are critical components of a comprehensive strategy to address this crisis.

FUTURE DIRECTIONS

Ultimately, combating bacterial resistance requires a multifaceted approach that integrates microbiological research, clinical advancements, public health policies, and global collaboration. Strengthening international efforts to monitor resistance patterns, investing in the development of novel therapeutics, and promoting responsible antibiotic use will be key to curbing the growing threat of bacterial resistance. Future research should focus on innovative antimicrobial strategies, improved diagnostic tools, and sustainable public health interventions to ensure that effective treatment options remain available for future generations.

REFERENCES

1. Fletcher S. Understanding the contribution of environmental factors in the spread of antimicrobial resistance. Environmental Health and Preventive Medicine [Internet]. 2015 Jul 1 [cited 2025 Feb 6];20(4):243–52. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491066/
2. Tao S, Chen H, Li N, Wang T, Liang W. The Spread of Antibiotic Resistance Genes in Vivo Model. The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale [Internet]. 2022 Jul 18 [cited 2025 Feb 6];2022(1):3348695. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9314185/
3. Sultan I, Rahman S, Jan AT, Siddiqui MT, Mondal AH, Haq QMR. Antibiotics, Resistome and Resistance Mechanisms: A Bacterial Perspective. Frontiers in Microbiology [Internet]. 2018 Sep 21 [cited 2025 Feb 6];9(1). Available from: https://doi.org/10.3389/fmicb.2018.02066
4. Department of Health and Human Services. How Antibiotic Resistance Moves Directly Germ to Germ [Internet]. 2023 [cited 2025 Feb 7]. Available from: https://www.cdc.gov/antimicrobial-resistance/media/pdfs/how-ar-moves-508.pdf?CDC_AAref_Val=https://www.cdc.gov/drugresistance/pdf/threats-report/How-AR-Moves-508.pdf
5. Gaurav A, Bakht P, Saini M, Pandey S, Pathania R. Role of bacterial efflux pumps in antibiotic resistance, virulence, and strategies to discover novel efflux pump inhibitors. Microbiology Society [Internet]. 2023 May 24 [cited 2025 Feb 6];169(5). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10268834/
6. Yu EW, Zhang Q, Brown MH. Microbial Efflux Pumps: Current Research [Internet]. Caister.com. 2024 [cited 2025 Feb 6]. Available from: https://doi.org/10.21775/9781910190753
7. Nishino K, Yamasaki S, Nakashima R, Zwama M, Hayashi-Nishino M. Function and Inhibitory Mechanisms of Multidrug Efflux Pumps. Frontiers in Microbiology [Internet]. 2021 Dec 3 [cited 2025 Feb 6];12(1). Available from: https://doi.org/10.3389/fmicb.2021.737288
8. Lorusso AB, Carrara JA, Barroso CDN, Tuon FF, Faoro H. Role of Efflux Pumps on Antimicrobial Resistance in Pseudomonas aeruginosa. International Journal of Molecular Sciences [Internet]. 2022 Dec 13 [cited 2025 Feb 6];23(24):15779. Available from: https://www.mdpi.com/1422-0067/23/24/15779
9. Chiang AD, Dekker JP. Efflux pump-mediated resistance to new beta lactam antibiotics in multidrug-resistant gram-negative bacteria. Communications Medicine. 2024 Aug 29;4(1).
10. World Health Organization. ANTIMICROBIAL RESISTANCE Global Report on Surveillance [Internet]. 2014 [cited 2025 Feb 6]. Available from: https://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng.pdf
11. Batchelder JI, Hare PJ, Mok WWK. Resistance-resistant antibacterial treatment strategies. Frontiers in Antibiotics [Internet]. 2023 [cited 2025 Feb 6];2(1):1093156. Available from: https://pubmed.ncbi.nlm.nih.gov/36845830/
12. Murray CJL. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 [Internet]. Doi.org. 2024 [cited 2024 Feb 6]. Available from: https://doi.org/10.1016/%20S0140-6736(24)01867-1
13. Markley JD, Bernard S, Delacruz O. Combination Antibiotic Therapy for the Definitive Management of Select Multidrug-Resistant Gram-Negative Rod Infections. Current Treatment Options in Infectious Diseases [Internet]. 2015 Oct 19 [cited 2025 Feb 6];7(4):273–90. Available from: https://link.springer.com/article/10.1007/s40506-015-0066-0
14. Tufts University. What Is Combination Drug Therapy? [Internet]. Tufts.edu. 2022 [cited 2025 Feb 6]. Available from: https://medicine.tufts.edu/news-events/news/what-combination-drug-therapy
15. Urban-Chmiel R, Marek A, Stępień-Pyśniak D, Wieczorek K, Dec M, Nowaczek A, et al. Antibiotic Resistance in Bacteria—A Review. Antibiotics [Internet]. 2022 Aug 1 [cited 2025 Feb 6];11(8):1079. Available from: https://www.mdpi.com/2079-6382/11/8/1079/htm
16. Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, Present and Future. Current Opinion in Microbiology [Internet]. 2019 Oct [cited 2025 Feb 6];51(1):72–80. Available from: https://www.sciencedirect.com/science/article/pii/S1369527419300190
17. Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, et al. Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare [Internet]. 2023 Jan 1 [cited 2025 Feb 6];11(13):1946. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10340576/
18. Iskandar K, Molinier L, Hallit S, Sartelli M, Hardcastle TC, Haque M, et al. Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered picture. Antimicrobial Resistance & Infection Control [Internet]. 2021 Mar 31 [cited 2025 Feb 6];10(1). Available from: https://aricjournal.biomedcentral.com/articles/10.1186/s13756-021-00931-w
19. Struelens MJ. The epidemiology of antimicrobial resistance in hospital acquired infections: problems and possible solutions. BMJ [Internet]. 1998 Sep 5 [cited 2025 Feb 6];317(7159):652–4. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC1113836/
20. Ahmed SK, Husein S, Qurbani K, Ibrahim RH, Fareeq A, Mahmood KA, et al. Antimicrobial resistance: Impacts, challenges, and future prospects. Journal of Medicine Surgery and Public Health [Internet]. 2024 Mar 1 [cited 2025 Feb 6];2(100081):100081–1. Available from: https://doi.org/10.1016/j.glmedi.2024.100081